Sehested M - Search Results

1

In vitro models for testing of cytostatic agents in small cell lung cancer.

Jensen PB, Sehested M. Jensen PB, et al. Among authors: sehested m. Cancer Treat Res. 1995;72:171-91. doi: 10.1007/978-1-4615-2630-8_9. Cancer Treat Res. 1995. PMID: 7702986 Review. No abstract available.

2

Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alpha.

Wessel I, Jensen LH, Renodon-Corniere A, Sorensen TK, Nitiss JL, Jensen PB, Sehested M. Wessel I, et al. Among authors: sehested m. FEBS Lett. 2002 Jun 5;520(1-3):161-6. doi: 10.1016/s0014-5793(02)02805-3. FEBS Lett. 2002. PMID: 12044890 Free article.

3

Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.

Jensen LH, Thougaard AV, Grauslund M, Søkilde B, Carstensen EV, Dvinge HK, Scudiero DA, Jensen PB, Shoemaker RH, Sehested M. Jensen LH, et al. Among authors: sehested m. Cancer Res. 2005 Aug 15;65(16):7470-7. doi: 10.1158/0008-5472.CAN-05-0707. Cancer Res. 2005. PMID: 16103101

4

Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity.

Jensen PB, Roed H, Sehested M, Demant EJ, Vindeløv L, Christensen IJ, Hansen HH. Jensen PB, et al. Among authors: sehested m. Cancer Chemother Pharmacol. 1992;31(1):46-52. doi: 10.1007/BF00695993. Cancer Chemother Pharmacol. 1992. PMID: 1360876

5

Relationship of VP-16 to the classical multidrug resistance phenotype.

Sehested M, Friche E, Jensen PB, Demant EJ. Sehested M, et al. Cancer Res. 1992 May 15;52(10):2874-9. Cancer Res. 1992. PMID: 1581902

6

Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II.

Jensen PB, Jensen PS, Demant EJ, Friche E, Sørensen BS, Sehested M, Wassermann K, Vindeløv L, Westergaard O, Hansen HH. Jensen PB, et al. Among authors: sehested m. Cancer Res. 1991 Oct 1;51(19):5093-9. Cancer Res. 1991. PMID: 1655244

7

The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.

Friche E, Jensen PB, Sehested M, Demant EJ, Nissen NN. Friche E, et al. Among authors: sehested m. Cancer Commun. 1990;2(9):297-303. Cancer Commun. 1990. PMID: 1976341

8

Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.

Jensen PB, Sørensen BS, Demant EJ, Sehested M, Jensen PS, Vindeløv L, Hansen HH. Jensen PB, et al. Among authors: sehested m. Cancer Res. 1990 Jun 1;50(11):3311-6. Cancer Res. 1990. PMID: 2159380

9

In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL).

Jensen PB, Vindeløv L, Roed H, Demant EJ, Sehested M, Skovsgaard T, Hansen HH. Jensen PB, et al. Among authors: sehested m. Br J Cancer. 1989 Dec;60(6):838-44. doi: 10.1038/bjc.1989.376. Br J Cancer. 1989. PMID: 2574988 Free PMC article.

10

Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.

Sorensen M, Sehested M, Jensen PB. Sorensen M, et al. Among authors: sehested m. Br J Cancer. 1995 Aug;72(2):399-404. doi: 10.1038/bjc.1995.345. Br J Cancer. 1995. PMID: 7640225 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

152 results

Search Page

Filters